A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic

Drug repurposing is the only method capable of delivering treatments on the shortened time-scale required for patients afflicted with lung disease arising from SARS-CoV-2 infection. Mucin-1 (MUC1), a membrane-bound molecule expressed on the apical surfaces of most mucosal epithelial cells, is a bioc...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:bioRxiv
Asıl Yazarlar: Alimova, Maria, Sidhom, Eriene-Heidi, Satyam, Abhigyan, Dvela-Levitt, Moran, Melanson, Michelle, Chamberlain, Brian T., Alper, Seth L., Santos, Jean, Gutierrez, Juan, Subramanian, Ayshwarya, Grinkevich, Elizabeth, Bricio, Estefania Reyes, Kim, Choah, Clark, Abbe, Watts, Andrew, Thompson, Rebecca, Marshall, Jamie, Pablo, Juan Lorenzo, Coraor, Juliana, Roignot, Julie, Vernon, Katherine A., Keller, Keith, Campbell, Alissa, Emani, Maheswarareddy, Racette, Matthew, Bazua-Valenti, Silvana, Padovano, Valeria, Weins, Astrid, McAdoo, Stephen P., Tam, Frederick W.K., Ronco, Lucienne, Wagner, Florence, Tsokos, George C., Shaw, Jillian L., Greka, Anna
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Cold Spring Harbor Laboratory 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7337390/
https://ncbi.nlm.nih.gov/pubmed/32637960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.30.180380
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller